Download PDF
Thromb Haemost 1982; 48(03): 263-265
DOI: 10.1055/s-0038-1657276
Original Article
Schattauer GmbH Stuttgart

The Effect of Oral Contraceptives on Coagulation and Fibrinolytic Parameters in the Chinese – A Prospective Study

Vivian Wong
The Department of Obstetrics and Gynaecology and Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong
,
T K Chan
The Department of Obstetrics and Gynaecology and Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong
,
Vivian Chan
The Department of Obstetrics and Gynaecology and Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong
,
S C Tso
The Department of Obstetrics and Gynaecology and Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong
,
D Todd
The Department of Obstetrics and Gynaecology and Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong
,
H K Ma
The Department of Obstetrics and Gynaecology and Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong
› Author Affiliations
Further Information

Publication History

Received 03 May 1982

Accepted 09 September 1982

Publication Date:
13 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Thirty-two Chinese and 7 Caucasians were studied prospectively for 12 months for the effects of oral contraceptives (OC) on certain coagulation and fibrinolytic parameters. In both ethnic groups there was an increase in α1 antitrypsin level. There was no significant change in antithrombin III concentration measured either by radioimmunoassay (At-III-RIA) or chromogenic assay (anti Xa-chromogenic) in the Chinese, but a significant decrease in anti Xa-chromogenic at 7 months and At-III-RIA at 12 months in the Caucasians. Also, α2 plasmin inhibitor (α2PI) levels were unchanged in the Chinese but a significant increase occurred in the Caucasians at 12 months. Enhanced fibrinolytic response to venous occlusion was demonstrated in the Chinese at 12 months but not in the Caucasians.

Keywords

Oral contraceptives - Antithrombin III - α2 plasmin inhibitor - Fibrinolytic response - Chinese - Caucasians
 

  • References

  • 1 Royal College of General Practitioners Oral Contraception Study. Oral contraceptives, venous thrombosis and varicose veins. J R Coll Gen Practitioners 1978; 28: 393-399
    PubMedGoogle Scholar
  • 2 Vessey M, Doll R, Peto R, Johnson B, Wiggins P. A long-term follow-up study of women using different methods of contraception – an interim report. J Biosocial Sci 1976; 8: 375-427
    PubMedGoogle Scholar
  • 3 Poller L. Oral contraceptives, blood clotting and thrombosis. Br Med Bull 1978; 151-156
    PubMedGoogle Scholar
  • 4 von Kaulla E, von Kaulla KN. Oral contraceptives and low antithrombin III activity. Lancet 1970; 1: 36
    PubMedGoogle Scholar
  • 5 Fagerhol MK, Abildgaard U, Bergsjo P, Jacobsen JH. Oral contraceptives and low antithrombin III concentration. Lancet 1970; 1: 1175
    PubMedGoogle Scholar
  • 6 Sagar S, Stamatakis JP, Thomas DP, Kakkar VV. Oral contraceptives, antithrombin III activity and postoperative deep vein thrombosis. Lancet 1971; 1: 509-511
    PubMedGoogle Scholar
  • 7 Tso SC, Wong V, Chan V, Chan TK, Ma HK, Todd D. Deep vein thrombosis and changes in coagulation and fibrinolysis after gynaecological operations in Chinese – the effect of oral contraceptives and malignant disease. Br J Haematol 1980; 46: 603-612
    CrossrefPubMedGoogle Scholar
  • 8 Chan TK, Chan V. The effects of venous occlusion on antithrombin III, plasminogen activator and fibrinogen degradation product (Fragment E) levels. Thromb Res 1979; 14: 525-534
    CrossrefPubMedGoogle Scholar
  • 9 Martin MJ, Gordon YB, Ratky SM, Baker LRI, Chard T. Conditions for collection of serum samples for the measurement of fibrin(ogen) degradation products by radioimmunoassay of fragment. Eur J Clin Pathol 1976; 29: 336-340
    PubMedGoogle Scholar
  • 10 Proctor RR, Rapaport SI. The partial thromboplastin time with Kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol 1961; 35: 212-219
    PubMedGoogle Scholar
  • 11 Ratnoff OD, Menzie C. A new method for the determination of fibrinogen in small samples of plasma. J Lab, Clin Med 1951; 37: 316-320
    PubMedGoogle Scholar
  • 12 Denson KWE. The specific assay of Prower-Stuart factor and factor VII. Acta Haematol 1961; 25: 105-120
    CrossrefPubMedGoogle Scholar
  • 13 Chan V, Chan TK, Wong V, Tso SC, Todd D. The determination of antithrombin III by radioimmunoassay and its clinical application. Br J Haematol 1979; 41: 563-572
    CrossrefPubMedGoogle Scholar
  • 14 Odegard OR, Lie M, Abildgaard U. Antifactor Xa activity measured with amidolytic methods. Haemostasis 1976; 5: 265-275
    PubMedGoogle Scholar
  • 15 Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochem 1965; 2: 235-254
    CrossrefPubMedGoogle Scholar
  • 16 Poller L, Thomson JE. Clotting factors during oral contraception: further report. Br Med J 1966; 2: 23-25
    CrossrefPubMedGoogle Scholar
  • 17 Howie PW, Mallinson AC, Prentice CRM, Horne CHW, McNicol GP. Effect of combined oestrogen-progestogen oral contraceptives, oestrogen and progestogen on antiplasmin and antithrombin activity. Lancet 1970; 2: 1329-1332
    PubMedGoogle Scholar
  • 18 Meade TW, Brozovic M, Chakrabarti R, Howarth DJ, North WRS, Stirling Y. An epidemiological study of the haemostatic and other effects of oral contraceptives. Br J Haematol 1976; 34: 353-364
    CrossrefPubMedGoogle Scholar
  • 19 Tsakok FHM, Koh S, Ratnam SS. Effects of oral contraceptives containing 50 μg estrogen on blood coagulation in non-Caucasian women. Contraception 1980; 21: 505-527
    CrossrefPubMedGoogle Scholar
  • 20 O’Brien JR. The Prothrombotic State. Recent Advances in Blood Coagulation. Poller L. (ed) Churchill Livingstone; Edinburgh: 1977: 241-266
    Google Scholar
  • 21 Lane JL, Biggs R. The natural inhibitors of coagulation: antithrombin III, heparin cofactor and antifactor XA. Recent Advances in Blood coagulation. Poller L. (ed) Churchill Livingstone; Edinburgh: 1977: 123-139
    Google Scholar
  • 22 Conard J, Cazenave B, Samana M, Horellon MH, Zorn JR, Nean C. At-III content and antithrombin activity in oestrogen-progestogen and progestogen-only treated women. Thromb Res 1980; 18: 675-681
    CrossrefPubMedGoogle Scholar
  • 23 Panicucci F, Sacripanti A, Pinori E, Vispi M, Conte B, Lecchini L. Antithrombin III, heparin cofactor and antifactor Xa in relation to age, sex and pathological conditions. Thromb Haemostas 1979; 42: 127 (Abst. 0294)
    PubMedGoogle Scholar
  • 24 Meade TW, Chakrabarti R, Haines AP, Howarth DJ, North WRS, Stirling Y. Haemostatic, lipid and blood-pressure profiles of women on oral contraceptives containing 50 μg or 30 μg oestrogen. Lancet 1977; 2: 948-951
    PubMedGoogle Scholar
  • 25 Collen D. Identification and some properties of a new fast reacting plasmin inhibitor in human plasma. Eur J Biochem 1976; 69: 209-216
    CrossrefPubMedGoogle Scholar
  • 26 Aoki N. Natural inhibitors of fibrinolysis. Progress in Cardiovascular Diseases. Sonnenblick EH, Lesch M. (eds). 21 Grune & Stratton; New York: 1979: 267-286
    Google Scholar
  • 27 Isacson S, Nilsson IM. Defective fibrinolysis in blood and vein walls in recurrent “idiopathic” venous thrombosis. Acta Chir Scand 1972; 138: 313-319
    PubMedGoogle Scholar